This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Domanski, M. Search for Related Content PubMed PubMed Citation Articles by Domanski, M.

The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial

Michael Domanski, MD^*,*, Heidi Krause-Steinrauf, MS^*, Prakash Deedwania, MD, Dean Follmann, PhD^*, Jalal K. Ghali, MD, Edward Gilbert, MD^||, Steven Haffner, MD, Richard Katz, MD^¶, JoAnn Lindenfeld, MD^#, Brian D. Lowes, MD^#, Wade Martin, MD^**, Frank McGrew, MD, Michael R. Bristow, MD, PhD^# BEST Investigators

^* Clinical Trials Group, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
University of Texas Health Science Center, San Antonio, Texas, USA
Fresno VAMC, Fresno, California, USA
Cardiac Centers of Louisiana, Shreveport, Louisiana USA
^|| University of Utah Health Science Center, Salt Lake City, Utah, USA
^¶ Division of Cardiology, George Washington University, Washington, DC, USA
^# Division of Cardiology, University of Colorado, Denver, Colorado, USA
^** St. Louis VAMC, St. Louis, Missouri, USA
Baptist Memorial Hospital, Memphis, Tennessee, USA

View larger version (29K): [in a new window]   Figure 1 Survival of patients according to diabetic and coronary artery disease status in the entire cohort (placebo or bucindolol treatment). Hazard ratio (HR) and 95% confidence interval compare diabetics to nondiabetics. Estimates are adjusted for treatment group assignment. CAD = coronary artery disease (ischemic cardiomyopathy); DM = diabetes mellitus.

View larger version (17K): [in a new window]   Figure 2 Effect of bucindolol or placebo treatment on the combined end point of death or heart failure hospitalization, in the entire cohort (A), diabetics (B), and nondiabetics (C).